Pharmacovigilance of Biosimilars from a regulatory point of view: Is there a need for a specific approach?

T.J. Giezen; S.M.J.M. Straus; A.K. Mantel-Teeuwisse

Pharmacovigilance of Biosimilars from a regulatory point of view: Is there a need for a specific approach?

T.J. Giezen, S.M.J.M. Straus, A.K. Mantel-Teeuwisse

Dept of Pharmaceutical Sciences

extern

Research output: Contribution to journal › Article › Academic › peer-review

Original language	Undefined/Unknown
Pages (from-to)	53-58
Number of pages	6
Journal	The international journal of risk and safety in medicine
Volume	21
Publication status	Published - 2009

Keywords

Farmacie/Biofarmaceutische wetenschappen (FARM)
Epidemiology
Farmacie(FARM)
Biomedische technologie en medicijnen
Ziekenhuisstructuur en organisatie van de gezondheidszorg
Public Health

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{06288f9befb0416c939a5ad1a7046ab2,

title = "Pharmacovigilance of Biosimilars from a regulatory point of view: Is there a need for a specific approach?",

keywords = "Farmacie/Biofarmaceutische wetenschappen (FARM), Epidemiology, Farmacie(FARM), Biomedische technologie en medicijnen, Ziekenhuisstructuur en organisatie van de gezondheidszorg, Public Health",

author = "T.J. Giezen and S.M.J.M. Straus and A.K. Mantel-Teeuwisse",

year = "2009",

language = "Undefined/Unknown",

volume = "21",

pages = "53--58",

journal = "The international journal of risk and safety in medicine",